One year from now, page-22

Thanks S2m... with the updating of our website, there's a number of interesting media article and vids to be seen! The interview with our man Dan Shelly is very interesting and all but indicates tthat our OmniCAR trial in AML is going to utilise allogeneic "off the shelf" cells. That is rather big news... the only downside is that commencement of that clinical trial won't be until next year (which is the timeline the co. originally anitcipated for OmniCAR).


https://www.cgtlive.com/view/dan-shelly-phd-developing-allogeneic-adaptable-car-platform


Leap frogging into allo (based on DS's reasoning) would position us well and truly at the forefront of Next Gen immonotherapy and ahead of the crowd which is a real positive. Just got to convince tthe FDA given that auto is the "accepted" method to date. Are our trials in HER2-solid tumours and GBM taking the same route... and is Thermo Fisher expediting the allogeneic approach in our collab? It's likely that our automated, closed, non-viral vector cell manufacturing system design is agnostic on donor method (allo or auto).

So, just how many binders does MD Anderson actually have in their library that correlate to AML, I wonder.